PBI-0451 Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 double-blind, randomized study of PBI-0451 in nonhospitalized symptomatic
adults with COVID-19. PBI-0451 is a new chemical entity and inhibitor of the main protease of
coronaviruses, including the SARS-CoV-2 that causes COVID-19 disease. This study is designed
to evaluate the antiviral activity, safety, and efficacy of orally administered PBI-0451
compared with placebo.